Skip to main content
Clinical Trials/NCT02616432
NCT02616432
Active, not recruiting
Not Applicable

Tomosynthesis Mammography Imaging Screening Trial Lead-in

Sunnybrook Health Sciences Centre4 sites in 1 country3,065 target enrollmentOctober 2014
ConditionsBreast Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Sunnybrook Health Sciences Centre
Enrollment
3065
Locations
4
Primary Endpoint
Diagnostic Accuracy of DBT vs FFDM - AUC under ROC comparison
Status
Active, not recruiting
Last Updated
11 months ago

Overview

Brief Summary

A randomized screening trial to compare the diagnostic accuracy of screening for breast cancer with three-dimensional digital breast tomosynthesis (DBT) plus two-dimensional full-field digital mammography (FFDM) versus FFDM alone.

Detailed Description

The Tomosynthesis Mammography Imaging Screening Trial (TMIST) LEAD-IN is being conducted to ensure that all Eastern Cooperative Oncology Group / American College of Radiology Imaging Network (ECOG/ACRIN) TMIST components are properly functional and to provide an opportunity for fine tuning before launching the full TMIST. The accrual target for TMIST LEAD-IN is 6354 participants (one tenth of the projected enrollment target for TMIST) at three lead-in study sites: 1. Sunnybrook Health Sciences Centre in Toronto, 2. Vancouver (under the auspices of the Screening Mammography Programme of British Columbia) and 3. The Ottawa Hospital.

Registry
clinicaltrials.gov
Start Date
October 2014
End Date
December 2027
Last Updated
11 months ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Roberta Jong

Principal Investigator

Sunnybrook Health Sciences Centre

Eligibility Criteria

Inclusion Criteria

  • Asymptomatic women age 40 and over
  • Scheduled for screening mammogram
  • Able to tolerate digital breast tomosynthesis and full-field digital mammographic imaging required by protocol
  • Willing and able to provide a written informed consent.

Exclusion Criteria

  • Presenting for mammography with symptoms of breast disease
  • Have new breast complaints (e.g. lump, nipple discharge)
  • Have had a mammogram of both breasts within the last 11 months
  • Previous personal history of breast cancer
  • Has breast enhancements (e.g. implants or injections)
  • Pregnancy or intent to become pregnant.

Outcomes

Primary Outcomes

Diagnostic Accuracy of DBT vs FFDM - AUC under ROC comparison

Time Frame: 3 year follow-up

To compare the diagnostic accuracy using the area under the curve (AUC) score generated by receiver operator characteristic (ROC) analysis of digital breast tomosynthesis plus full-field digital mammography (DBT) versus full-field digital mammography (FFDM) alone for breast cancer screening. The examinations will be interpreted by local Breast Imaging radiologists. Cancer status will be pathologically confirmed. The women would undergo three consecutive screening rounds in the assigned arm followed by one year of standard of care imaging follow-up.

Secondary Outcomes

  • Recall Rates(3 year)
  • Interval Cancers(3 year)
  • Prevalence of Breast Cancer Subtypes(3 year)
  • Reader Studies of variations of DBT vs FFDM - AUC under ROC comparison(4 year)
  • Biomarker Correlation(2 year)
  • Clinical Characteristics of Cancers(3 year)

Study Sites (4)

Loading locations...

Similar Trials